Biotechnology - Neurological, Teva Pharmaceutical Industries, Boardroom

Teva pulls out of CureTech deal; AC Immune drops CI-91


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration…

AC ImmuneBiotechnologyCT-011CureTechLicensingNeurologicalOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst


Following the September 2010 US launch, Swiss drug major Novartis’ (NOVN: VX) first-in-class, once-daily…

AubagioBiogen IdecBiotechnologyGilenyalaquinimodLemtradaMarkets & MarketingNeurologicalNovartisocrelizumabPharmaceuticalResearchRocheSanofiTeva Pharmaceutical Industries

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon


As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Back to top